9
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      High-Grade Heart Block Requiring Transvenous Pacing Associated with Multisystem Inflammatory Syndrome in Children During the COVID-19 Pandemic

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction Multisystem Inflammatory Syndrome in Children (MIS-C) has recently been described in pediatric patients associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) during the Coronavirus Disease 2019 (COVID-19) pandemic.1, 2, 3 Although MIS-C is commonly associated with cardiovascular findings, the occurrence of arrhythmias is rare. We present the case of a pediatric patient who developed severe hemodynamic instability and high-grade heart block associated with MIS-C requiring transvenous pacing. Case Report: In early April 2020, an 11-year-old previously healthy male (weight 59.3 kg, body mass index 24.2 kg/m2) presented with a week of fever to 39.5oC, dyspnea and a 4-week history of cough. One day prior to admission, he developed a rash and conjunctival injection. Vital signs on admission included a heart rate of 138, a blood pressure of 87/57, a respiratory rate of 28, a saturation in room air of 98% and a temperature of 38oC. Pertinent physical exam findings revealed perilimbal conjunctival injection, diminished breath sounds with crackles in the right upper lobe, mild distress and a polymorphic maculopapular rash over the torso and trunk. The patient had no significant past medical history. The differential diagnosis included bacterial and viral pneumonia. Toxic shock syndrome, early Stevens-Johnson syndrome and Kawasaki disease were also considered. Possible infectious etiologies included an adenovirus, Mycoplasma pneumoniae, Group A Streptococcus and Staphylococcus aureus. Given the COVID-19 pandemic, infection with SARS-CoV-2 was also considered. An initial radiograph demonstrated a multifocal right-sided pneumonia. His respiratory panel was positive for Mycoplasma pneumoniae, and treatment with azithromycin was begun. His SARS-CoV-2 RNA RT PCR testing was negative. Laboratory investigations demonstrated a hyperinflammatory state (CRP 330.9 mg/L, ESR 110 mm/hr, ferritin 509 ng/mL and D-Dimer 7.67 mCg/mL FEU), neutrophilia and lymphopenia. Interleukin-2 receptor and interleukin-6 were markedly elevated at 56,818 PG/mL and 534.71 PG/mL, respectively. Within 24 hours of admission, he developed worsening hypoxia and hypotension, requiring high-flow nasal cannula support (15 liters per minute, 50% FiO2) and 80 mL/kg crystalloid fluid resuscitation, prompting transfer to the pediatric intensive care unit. Antibiotic coverage was broadened to levofloxacin and linezolid. An echocardiogram demonstrated an ectatic right coronary artery (RCA) with a z-score of 5.16 with loss of distal tapering, a normal left main coronary artery (LMCA) and an ectatic left anterior descending coronary artery (LAD) with a z-score of 2.4 with loss of distal tapering. There was normal cardiac function. He received 2 mg/kg of intravenous immunoglobulin (IVIG) and medium-dose aspirin, consistent with Kawasaki disease treatment. During hospital days 2-3, the patient developed vasogenic shock and rising lactate levels, requiring intubation and a norepinephrine infusion. He had persistent fevers (up to 39.9oC) and worsening rash. Small bilateral pleural effusions developed. Serial echocardiograms showed further coronary artery dilation and ectasia, with an RCA z-score of 13.5, an LMCA z-score of 4.8 and an LAD z-score of 7.05. The apical 4-chamber left ventricular ejection fraction was normal at 74%. Active anticoagulation commenced with unfractionated heparin, and a second dose of IVIG was given. Early electrocardiograms demonstrated normal sinus rhythm without evidence of ischemia. Serial troponin levels remained <0.01 ng/mL. On hospital day 4, the patient’s clinical status worsened further requiring escalation in vasomotor support and the addition of a vasopressin infusion to maintain a systolic blood pressure > 80 mmHg. He developed conduction abnormalities, including sinus bradycardia with varying degrees of atrioventricular conduction abnormalities (first- and second-degree heart block), intraventricular conduction abnormalities with varying QRS morphologies and periods of an idioventricular rhythm. Despite a normal left ventricular ejection fraction, the relative bradycardia contributed to decreased cardiac output, oliguric renal failure and a rising lactate level, which peaked at 14.7 mmol/L. He had a brief run of non-sustained ventricular tachycardia (7 beats with cycle length of 220 milliseconds). He then developed second-degree type II heart block with variable nonspecific intraventricular conduction delay (Figure 1 ). His heart rate ranged from 75-89 beats per minute. This was deemed an insufficient heart rate based on his age, severity of illness and markers of inadequate oxygen delivery. An emergent transvenous bipolar pacing catheter (Edwards Lifesciences, Irvine, CA) was inserted at the bedside, and ventricular pacing was initiated at a VVI rate of 110 beats per minute. One gram of methylprednisolone was given. Repeat SARS-CoV-2 RNA RT PCR testing was negative, and antibiotics were changed to ceftaroline and doxycycline. The extracorporeal membrane oxygenation team was alerted for possible cannulation should the patient’s status continue to decline. Figure 1 Electrocardiogram demonstrating second-degree type II heart block. A few hours after the initiation of transvenous pacing and methylprednisolone, the lactate level decreased, and his blood pressure stabilized. The following day, his conduction system abnormalities improved, progressing to second-degree type I block (Figure 2 ). Approximately 48 hours later, he was noted to have first-degree atrioventricular block, and we were able to safely discontinue transvenous pacing. This was followed by complete resolution of atrioventricular and intraventricular conduction abnormalities, a return to normal sinus rhythm (Figure 3 ), cessation of vasoactive support and extubation. Figure 2 Electrocardiogram demonstrating second-degree type I heart block with intermittent aberrant conduction. Figure 3 Electrocardiogram demonstrating normal sinus rhythm Despite continued steroid administration and clinical recovery of all other organs, his coronary artery dilation progressed to severe diffuse coronary ectasia with an aneurysm of the proximal RCA and an aneurysm of the LAD. Maximum z-scores were 13.95 for the RCA and 19.9 for the proximal LAD. This prompted administration of infliximab. Magnetic resonance imaging of the chest and abdomen showed no evidence of systemic vasculitis. His conduction remained intact throughout the rest of his hospitalization, and he was discharged home in good condition. Discussion: Just prior to discharge, the United Kingdom National Health Service released an alert regarding “a new phenomenon affecting previously asymptomatic children with SARS-CoV-2 infection manifesting as a hyperinflammatory syndrome with multiorgan involvement similar to Kawasaki disease shock syndrome,” now termed MIS-C. 1 , 2 Serologic testing for SARS-CoV-2 using an ELISA assay (Epitope Diagnostics, Inc., San Diego, CA) confirmed the presence of anti-COVID-19 nucleocapsid IgG. The serologic ELISA assay testing for the presence of IgM was negative. Suggested exclusion criteria for the diagnosis of MIS-C is evidence of another infectious etiology. 4 Although this patient tested positive for Mycoplasma pneumoniae, his hyperinflammatory state, coronary artery dilation and high-grade heart block were not consistent with Mycoplasma. COVID-19 coinfection with Mycoplasma pneumoniae has been previously reported.5, 6, 7, 8 MIS-C has been associated with cardiac involvement and negative SARS-CoV-2 testing. 9 , 10 While the development of conduction system abnormalities including high-grade heart block is a known complication of coronary ischemia, 11 fulminant myocarditis 12 and Kawasaki Disease with severe coronary involvement, 13 this is the first case report describing high-grade heart block as a complication of MIS-C associated with SARS-CoV-2 requiring transvenous pacing. In one reported cohort of 186 MIS-C patients from the United States, 12% had an associated arrhythmia, however no specifics regarding the types of arrythmias seen were described in the publication. 3 In another MIS-C publication describing 35 children from France and Switzerland, one patient with an unspecified ventricular arrhythmia was reported. 10 Severe local inflammation and/or insufficiency of the coronary arterial supply to the atrioventricular node and specialized conduction system are the presumed mechanisms of the conduction system abnormalities in our patient. Interestingly, during his high-grade heart block, he had at least two different QRS morphologies suggesting either rare intermittent atrioventricular conduction with some degree of aberrancy or competing junctional and ventricular escape mechanisms. Regardless of the exact mechanism of the variable intraventricular conduction during bradycardia, the resulting cardiac output was insufficient to meet his metabolic demands. Although the therapeutic strategy was unproven in this clinical scenario, we speculate that the treatment aimed at mitigating a profound inflammatory response, namely the combination of methylprednisolone and IVIG, likely reversed the conduction system insult in our patient. Transvenous pacing was initiated on hospital day 4 and stopped on hospital day 6. Given the previously unknown entity of MIS-C at the time, inflammatory markers were not all closely trended. However, on hospital days 4, 5 and 7, the patient’s CRP was 266.5, 210 and 32.2 mg/L, respectively. In addition, on hospital days 3, 5, 6 and 7, the patient’s D-Dimer was 8.80, 3.71, 3.14 and 2.76 mCg/mL FEU, respectively. After a 4-week hospital stay, the patient was discharged home in good condition on enoxaparin and aspirin. At cardiology follow-up 6 weeks after the onset of illness, his coronary arteries remained significantly dilated, but sinus node rate, atrioventricular conduction and intraventricular conduction remained normal. Conclusions: To our knowledge, this is the first reported case of the development of high-grade heart block associated with MIS-C during the COVID-19 global pandemic to require transvenous pacing. The initiation of transvenous pacing along with the combination of aggressive anti-inflammatory therapies appeared to rapidly improve the patient’s condition and ultimately reverse the high-grade heart block. This case highlights that high-grade conduction system disease, including high-grade heart block, variable atrioventricular block and intraventricular conduction abnormalities, is a potential complication of MIS-C, requiring close observation and the need for advanced invasive cardiac intervention. Key Teaching Points 1. Multisystem Inflammatory Syndrome in Children (MIS-C) has recently been described in pediatric patients associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) during the Coronavirus Disease 2019 (COVID-19) pandemic. 2. Although cardiovascular involvement is common with MIS-C, rhythm disturbances are less commonly associated with the syndrome. 3. High-grade heart block is a potential complication of MIS-C, requiring close observation and the need for advanced invasive cardiac intervention, such as transvenous pacing.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: not found

          Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

          Abstract Background Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with coronavirus disease 2019 (Covid-19) is important, given the clinical and public health implications of the syndrome. Methods We conducted targeted surveillance for MIS-C from March 15 to May 20, 2020, in pediatric health centers across the United States. The case definition included six criteria: serious illness leading to hospitalization, an age of less than 21 years, fever that lasted for at least 24 hours, laboratory evidence of inflammation, multisystem organ involvement, and evidence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR), antibody testing, or exposure to persons with Covid-19 in the past month. Clinicians abstracted the data onto standardized forms. Results We report on 186 patients with MIS-C in 26 states. The median age was 8.3 years, 115 patients (62%) were male, 135 (73%) had previously been healthy, 131 (70%) were positive for SARS-CoV-2 by RT-PCR or antibody testing, and 164 (88%) were hospitalized after April 16, 2020. Organ-system involvement included the gastrointestinal system in 171 patients (92%), cardiovascular in 149 (80%), hematologic in 142 (76%), mucocutaneous in 137 (74%), and respiratory in 131 (70%). The median duration of hospitalization was 7 days (interquartile range, 4 to 10); 148 patients (80%) received intensive care, 37 (20%) received mechanical ventilation, 90 (48%) received vasoactive support, and 4 (2%) died. Coronary-artery aneurysms (z scores ≥2.5) were documented in 15 patients (8%), and Kawasaki’s disease–like features were documented in 74 (40%). Most patients (171 [92%]) had elevations in at least four biomarkers indicating inflammation. The use of immunomodulating therapies was common: intravenous immune globulin was used in 144 (77%), glucocorticoids in 91 (49%), and interleukin-6 or 1RA inhibitors in 38 (20%). Conclusions Multisystem inflammatory syndrome in children associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents. (Funded by the Centers for Disease Control and Prevention.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Hyperinflammatory shock in children during COVID-19 pandemic

            South Thames Retrieval Service in London, UK, provides paediatric intensive care support and retrieval to 2 million children in South East England. During a period of 10 days in mid-April, 2020, we noted an unprecedented cluster of eight children with hyperinflammatory shock, showing features similar to atypical Kawasaki disease, Kawasaki disease shock syndrome, 1 or toxic shock syndrome (typical number is one or two children per week). This case cluster formed the basis of a national alert. All children were previously fit and well. Six of the children were of Afro-Caribbean descent, and five of the children were boys. All children except one were well above the 75th centile for weight. Four children had known family exposure to coronavirus disease 2019 (COVID-19). Demographics, clinical findings, imaging findings, treatment, and outcome for this cluster of eight children are shown in the table . Table Demographics, clinical findings, imaging findings, treatment, and outcome from PICU Age; weight; BMI; comorbidities Clinical presentation Organ support Pharmacological treatment Imaging results Laboratory results Microbiology results PICU length of stay; outcome Initial PICU referral Patient 1 (male, AfroCaribbean) 14 years; 95 kg; BMI 33 kg/m2; no comorbidities 4 days >40°C; 3 days non-bloody diarrhoea; abdominal pain; headache BP 80/40 mmHg; HR 120 beats/min; RR 40 breaths per min; work of breathing; SatO2 99% NCO2 MV, RRT, VA-ECMO Dopamine, noradrenaline, argipressin, adrenaline milrinone, hydroxicortisone, IVIG, ceftriaxone, clindamycin RV dysfunction/elevate RVSP; ileitis, GB oedema and dilated biliary tree, ascites, bilateral basal lung consolidations and diffuse nodules Ferritin 4220 μg/L; D-dimers 13·4 mg/L; troponin 675 ng/L; proBNP >35 000; CRP 556 mg/L; procalcitonin>100 μg/L; albumin 20 g/L; platelets 123 × 109 SARS-CoV-2 positive (post mortem) 6 days; demise (right MCA and ACA ischaemic infarction) Patient 2 (male, AfroCaribbean) 8 years; 30 kg; BMI 18 kg/m2; no comorbidities 5 days >39°C; non-bloody diarrhoea; abdominal pain; conjunctivitis; rash BP 81/37 mmHg; HR 165 beats/min; RR 40 breaths/min; SVIA MV Noradrenaline, adrenaline, IVIG, infliximab, methylprednisolone, ceftriaxone, clindamycin Mild biventricular dysfunction, severely dilated coronaries; ascites, pleural effusions Ferritin 277 μg/L; D-dimers 4·8 mg/L; troponin 25 ng/L; CRP 295 mg/L; procalcitonin 8·4 μg/L; albumin 18 g/L; platelets 61 × 109 SARS-CoV-2 negative; likely COVID-19 exposure from mother 4 days; alive Patient 3 (male, Middle-Eastern) 4 years; 18 kg; BMI 17 kg/m2; no comorbidities 4 days >39°C; diarrhoea and vomiting; abdominal pain; rash; conjunctivitis BP 90/30 mmHg; HR 170 beats/min; RR 35 breaths/min; SVIA MV Noradrenaline, adrenaline, IVIG ceftriaxone, clindamycin Ascites, pleural effusions Ferritin 574 μg/L; D-dimers 11·7 mg/L; tropinin 45 ng/L; CRP 322 mg/L; procalcitonin 10·3 μg/L; albumin 22 g/L; platelets 103 × 109 Adenovirus positive; HERV positive 4 days; alive Patient 4 (female, AfroCaribbean) 13 years; 64 kg; BMI 33 kg/m2; no comorbidities 5 days >39°C; non-bloody diarrhoea; abdominal pain; conjunctivitis BP 77/41 mmHg; HR 127 beats/min; RR 24 breaths/min; SVIA HFNC Noradrenaline, milrinone, IVIG, ceftriaxone, clindamycin Moderate-severe LV dysfunction; ascites Ferritin 631 μg/L; D-dimers 3·4 mg/L; troponin 250 ng/L; proBNP 13427 ng/L; CRP 307 mg/L; procalcitonin 12·1 μg/L; albumin 21 g/L; platelets 146 × 109 SARS-CoV-2 negative 5 days; alive Patient 5 (male, Asian) 6 years; 22 kg; BMI 14 kg/m2; autism, ADHD 4 days >39°C; odynophagia; rash; conjunctivitis BP 85/43 mmHg; HR 150 beats/min; RR 50 breaths/min; SVIA NIV Milrinone, IVIG, methylprednisolone, aspirin, ceftriaxone Dilated LV, AVVR, pericoronary hyperechogenicity Ferritin 550 μg/L; D-dimers 11·1 mg/L; troponin 47 ng/L; NT-proBNP 7004 ng/L; CRP 183 mg/L; albumin 24 g/L; platelets 165 × 109 SARS-CoV-2 positive; likely COVID-19 exposure from father 4 days; alive Patient 6 (female, AfroCaribbean) 6 years; 26 kg; BMI 15 kg/m2; no comorbidities 5 days >39°C; myalgia; 3 days diarrhoea and vomiting; conjunctivitis BP 77/46 mmHg; HR 120 beats/min; RR 40 breaths/min; SVIA NIV Dopamine, noradrenaline, milrinone, IVIG, methylprednisolone, aspirin, ceftriaxone, clindamycin Mild LV systolic impairment Ferritin 1023 μg/L; D-dimers 9·9 mg/L; troponin 45 ng/L; NT-proBNP 9376 ng/L; CRP mg/L 169; procalcitonin 11·6 μg/L; albumin 25 g/L; platelets 158 SARS-CoV-2 negative; confirmed COVID-19 exposure from grandfather 3 days; alive Patient 7 (male, AfroCaribbean 12 years; 50kg; BMI 20 kg/m2; alopecia areata, hayfever 4 days >39°C; 2 days diarrhoea and vomiting; abdominal pain; rash; odynophagia; headache BP 80/48 mmHg; HR 125 beats/min; RR 47 breaths/min; SatO2 98%; HFNC FiO2 0.35 MV Noradrenaline, adrenaline, milrinone, IVIG, methylprednisolone, heparin, ceftriaxone, clindamycin, metronidazole Severe biventricular impairment; ileitis, ascites, pleural effusions Ferritin 958 μg/L; D-dimer 24·5 mg/L; troponin 813 ng/L; NT-proBNP >35 000 ng/L; CRP 251 mg/L; procalcitonin 71·5 μg/L; albumin 24 g/L; platelets 273 × 109 SARS-CoV-2 negative 4 days; alive Patient 8 (female, AfroCaribbean) 8 years; 50 kg; BMI 25 kg/m2; no comorbidities 4 days >39°C; odynophagia; 2 days diarrhoea and vomiting; abdominal pain BP 82/41 mmHg; HR 130 beats/min; RR 35 breaths/min; SatO2 97% NCO2 MV Dopamine, noradrenaline, milrinone, IVIG, aspirin, ceftriaxone, clindamycin Moderate LV dysfunction Ferritin 460 μg/L; D-dimers 4·3 mg/L; troponin 120 ng/L; CRP 347 mg/L; procalcitonin 7·42 μg/L; albumin 22 g/L; platelets 296 × 109 SARS-CoV-2 negative; likely COVID-19 exposure from parent 7 days; alive ACA= anterior cerebral artery. ADHD=attention deficit hyperactivity disorder. AVR=atrioventricular valve regurgitation. BMI=body mass index. BP=blood pressure. COVID-19=coronavirus disease 2019. CRP=C-reactive protein. FiO2=fraction of inspired oxygen. HERV=human endogenous retrovirus. HFNC=high-flow nasal canula. HR=heart rate. IVIG=human intravenous immunoglobulin. LV=left ventricle. MCA=middle cerebral artery. MV=mechanical ventilation via endotracheal tube. NIV=non-invasive ventilation. PICU=paediatric intensive care unit. RA=room air. RR=respiratory rate. RRT=renal replacement therapy. RV=right ventricle. RVSP=right ventricular systolic pressure. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. SatO2=oxygen saturation. SVIA=self-ventilating in air. VA-ECMO=veno-arterial extracorporeal membrane oxygenation. Clinical presentations were similar, with unrelenting fever (38–40°C), variable rash, conjunctivitis, peripheral oedema, and generalised extremity pain with significant gastrointestinal symptoms. All progressed to warm, vasoplegic shock, refractory to volume resuscitation and eventually requiring noradrenaline and milrinone for haemodynamic support. Most of the children had no significant respiratory involvement, although seven of the children required mechanical ventilation for cardiovascular stabilisation. Other notable features (besides persistent fever and rash) included development of small pleural, pericardial, and ascitic effusions, suggestive of a diffuse inflammatory process. All children tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on broncho-alveolar lavage or nasopharyngeal aspirates. Despite being critically unwell, with laboratory evidence of infection or inflammation 3 including elevated concentrations of C-reactive protein, procalcitonin, ferritin, triglycerides, and D-dimers, no pathological organism was identified in seven of the children. Adenovirus and enterovirus were isolated in one child. Baseline electrocardiograms were non-specific; however, a common echocardiographic finding was echo-bright coronary vessels (appendix), which progressed to giant coronary aneurysm in one patient within a week of discharge from paediatric intensive care (appendix). One child developed arrhythmia with refractory shock, requiring extracorporeal life support, and died from a large cerebrovascular infarct. The myocardial involvement 2 in this syndrome is evidenced by very elevated cardiac enzymes during the course of illness. All children were given intravenous immunoglobulin (2 g/kg) in the first 24 h, and antibiotic cover including ceftriaxone and clindamycin. Subsequently, six children have been given 50 mg/kg aspirin. All of the children were discharged from PICU after 4–6 days. Since discharge, two of the children have tested positive for SARS-CoV-2 (including the child who died, in whom SARS-CoV-2 was detected post mortem). All children are receiving ongoing surveillance for coronary abnormalities. We suggest that this clinical picture represents a new phenomenon affecting previously asymptomatic children with SARS-CoV-2 infection manifesting as a hyperinflammatory syndrome with multiorgan involvement similar to Kawasaki disease shock syndrome. The multifaceted nature of the disease course underlines the need for multispecialty input (intensive care, cardiology, infectious diseases, immunology, and rheumatology). The intention of this Correspondence is to bring this subset of children to the attention of the wider paediatric community and to optimise early recognition and management. As this Correspondence goes to press, 1 week after the initial submission, the Evelina London Children's Hospital paediatric intensive care unit has managed more than 20 children with similar clinical presentation, the first ten of whom tested positive for antibody (including the original eight children in the cohort described above).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

              In communities with high rates of coronavirus disease 2019, reports have emerged of children with an unusual syndrome of fever and inflammation.
                Bookmark

                Author and article information

                Contributors
                Journal
                HeartRhythm Case Rep
                HeartRhythm Case Rep
                HeartRhythm Case Reports
                Heart Rhythm Society. Published by Elsevier Inc.
                2214-0271
                25 August 2020
                25 August 2020
                Affiliations
                [a ]Division of Critical Care, Cardiovascular Intensive Care Unit, Children’s Hospital of Orange County, Orange, CA; University of California, Irvine, Irvine, CA
                [b ]Division of Cardiology, Children’s Hospital of Orange County, Orange, CA; University of California, Irvine, Irvine, CA
                [c ]Division of Infectious Disease, Children’s Hospital of Orange County, Orange, CA; University of California, Irvine, Irvine, CA
                [d ]Division of Hematology, Children’s Hospital of Orange County, Orange, CA; University of California, Irvine, Irvine, CA
                Author notes
                []Corresponding Author: Michele Domico, MD Children’s Hospital of Orange County 1201 W. La Veta Avenue Orange, CA 92868 mdomico@ 123456choc.org
                Article
                S2214-0271(20)30189-5
                10.1016/j.hrcr.2020.08.015
                7446646
                32864334
                81d12e21-ce21-4330-bd07-a1d1fc7dfc08
                © 2020 Heart Rhythm Society. Published by Elsevier Inc.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 12 June 2020
                : 13 August 2020
                : 17 August 2020
                Categories
                Article

                sars-cov-2,covid-19,second-degree heart block,multisystem inflammatory syndrome in children,transvenous pacing,covid-19, coronavirus disease 2019,sars-cov-2, severe acute respiratory syndrome coronavirus 2,mis-c, multisystem inflammatory syndrome in children

                Comments

                Comment on this article